This article therefore makes the limited statement that AOD9604 is not an FDA-approved therapeutic drug in the United States and does not claim to have exhaustively verified every human or veterinary regulatory database worldwide
(85 g) provides 93% of the DV (22,27)
Transient discolouration of tissue at the injection site is possible
Several candidates have emerged in recent research, including chemokines such as CXCL13, CXCL10, and CXCL8 [4, 34] although CXCL-13 is also an important biomarker for neuroborreliosis [35]
When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount
However, as Miller says, the research linking B12 with bone health only shows an association, not a cause-effect relationship